🚀 Transforming Drug Discovery Through AI Innovation
In a landmark collaboration, Lilly and NVIDIA have launched a groundbreaking AI co-innovation lab tailored for drug discovery advancements. Key highlights include:
- NVIDIA BioNeMo™ Expansion: An open development platform that transforms experimental data into actionable intelligence, enhancing R&D efficiency.
- Collaboration with Thermo Fisher: Focus on building autonomous lab infrastructures for streamlined scientific discovery.
- Ecosystem Involvement: Partnerships with leading innovators like Basecamp Research and Boltz PBC to leverage AI in molecular design and drug development.
Key Features of BioNeMo:
- New models for RNA structure prediction and drug synthesis validation.
- BioNeMo data libraries for optimized biological model training and deployment.
“Biology and drug discovery are at their transformer moments,” says Kimberly Powell, emphasizing the continuous learning cycle poised to revolutionize research.
🌍 Join the conversation on the future of AI in life sciences! Read more about these innovations and share your thoughts! 👇 #ArtificialIntelligence #Biotech #DrugDiscovery
